1182 related articles for article (PubMed ID: 11753595)
1. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
2. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
de Castro JJ; Dias T; Chambel P; Carvalheiro M; Correia LG; Guerreiro L; Marques O; Medina JL; Nobre E; Nunes JS; Pereiraa MC; Polónia J; Portugal J; Raimundo A; Ruas A; da Silva PM; Vasconcelos C; Reis JL; Teles AG
Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
[TBL] [Abstract][Full Text] [Related]
3. Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations.
Erdmann J; Lippl F; Klose G; Schusdziarra V
Aliment Pharmacol Ther; 2004 Jun; 19(11):1173-9. PubMed ID: 15153170
[TBL] [Abstract][Full Text] [Related]
4. A one-year trial to assess the value of orlistat in the management of obesity.
James WP; Avenell A; Broom J; Whitehead J
Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
Derosa G; Mugellini A; Ciccarelli L; Fogari R
Clin Ther; 2003 Apr; 25(4):1107-22. PubMed ID: 12809960
[TBL] [Abstract][Full Text] [Related]
6. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
[TBL] [Abstract][Full Text] [Related]
8. Orlistat use in overweight women with mild hypercholesterolemia.
Petrogiannopoulos C; Kalogeropoulos S; Latsios GS; Hartzoulakis G; Kalogeropoulos G; Zaharof A
Int J Clin Pharmacol Res; 2002; 22(3-4):85-8. PubMed ID: 12837045
[TBL] [Abstract][Full Text] [Related]
9. [Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].
Sjostrom L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar H; Krempf M;
Ter Arkh; 2000; 72(8):50-4. PubMed ID: 11019429
[TBL] [Abstract][Full Text] [Related]
10. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study.
Drent ML; Larsson I; William-Olsson T; Quaade F; Czubayko F; von Bergmann K; Strobel W; Sjöström L; van der Veen EA
Int J Obes Relat Metab Disord; 1995 Apr; 19(4):221-6. PubMed ID: 7627244
[TBL] [Abstract][Full Text] [Related]
11. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
[TBL] [Abstract][Full Text] [Related]
12. Effect of orlistat on cardiovascular disease risk in obese adults.
Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID
Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
[TBL] [Abstract][Full Text] [Related]
13. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity.
Krempf M; Louvet JP; Allanic H; Miloradovich T; Joubert JM; Attali JR
Int J Obes Relat Metab Disord; 2003 May; 27(5):591-7. PubMed ID: 12704403
[TBL] [Abstract][Full Text] [Related]
14. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial.
Anderson JW; Schwartz SM; Hauptman J; Boldrin M; Rossi M; Bansal V; Hale CA
Ann Pharmacother; 2006 Oct; 40(10):1717-23. PubMed ID: 16940406
[TBL] [Abstract][Full Text] [Related]
15. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.
Toplak H; Ziegler O; Keller U; Hamann A; Godin C; Wittert G; Zanella MT; Zúñiga-Guajardo S; Van Gaal L
Diabetes Obes Metab; 2005 Nov; 7(6):699-708. PubMed ID: 16219013
[TBL] [Abstract][Full Text] [Related]
16. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
[TBL] [Abstract][Full Text] [Related]
17. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
Finer N; James WP; Kopelman PG; Lean ME; Williams G
Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
[TBL] [Abstract][Full Text] [Related]
18. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
[TBL] [Abstract][Full Text] [Related]
19. Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients.
Kopelman P; Bryson A; Hickling R; Rissanen A; Rossner S; Toubro S; Valensi P
Int J Obes (Lond); 2007 Mar; 31(3):494-9. PubMed ID: 16953261
[TBL] [Abstract][Full Text] [Related]
20. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]